
INSM
Healthcare · Biotechnology · $26.58B market cap
$121.16+3.09 (+2.6%)Nov 13, 4:22 PM EST
Latest report
Before the open
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · +39.5% over 90 days · 30-day revisions 5 up, 9 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Oct 29, 2026 | Before the open | -0.34 | -0.46 | -35.3% |
| Aug 6, 2026 | Before the open | -0.69 | -0.52 | +24.6% |
| May 7, 2026 | Before the open | -1.00 | -0.76 | +24.0% |
| Feb 19, 2026 | Before the open | -1.17 | -1.54 | -31.6% |
| Oct 30, 2025 | Before the open | -1.37 | -1.75 | -27.7% |
| Aug 7, 2025 | Before the open | -1.30 | -1.70 | -30.8% |
| May 7, 2025 | Before the open | -1.20 | -1.42 | -18.3% |
| Feb 20, 2025 | Before the open | -1.23 | -1.32 | -7.3% |
| Oct 31, 2024 | Before the open | -1.22 | -1.27 | -4.1% |
| Aug 8, 2024 | Before the open | -1.23 | -1.94 | -57.7% |
| May 9, 2024 | Before the open | -1.20 | -1.06 | +11.7% |
| Feb 22, 2024 | Before the open | -1.13 | -1.28 | -13.3% |
| Oct 26, 2023 | Before the open | -1.11 |
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug…
| -1.11 |
| 0.0% |
| Aug 3, 2023 | Before the open | -1.12 | -1.78 | -58.9% |
| May 4, 2023 | Before the open | -1.10 | -1.17 | -6.4% |
| Feb 23, 2023 | Before the open | -1.04 | -1.21 | -16.3% |
| Oct 27, 2022 | Before the open | -0.87 | -1.09 | -25.3% |
| Aug 4, 2022 | Before the open | -0.89 | -0.80 | +10.1% |
| May 5, 2022 | Before the open | -0.87 | -0.80 | +8.0% |
| Feb 17, 2022 | Before the open | -0.86 | -0.95 | -10.5% |
| Oct 28, 2021 | Before the open | -0.78 | -0.96 | -23.1% |
| Aug 5, 2021 | Before the open | -0.88 | -0.91 | -3.4% |
| May 6, 2021 | Before the open | -0.96 | -0.89 | +7.3% |
| Feb 25, 2021 | Before the open | -0.70 | -1.00 | -42.9% |
| Oct 29, 2020 | Before the open | -0.59 | -0.63 | -6.8% |
| Aug 6, 2020 | Before the open | -0.62 | -0.64 | -3.2% |
| Apr 30, 2020 | Before the open | -0.72 | -0.74 | -2.8% |
| Feb 25, 2020 | Before the open | -0.58 | -0.59 | -1.7% |
| Oct 30, 2019 | Before the open | -0.67 | -0.68 | -1.5% |
| Aug 1, 2019 | Before the open | -0.86 | -0.81 | +5.8% |
| May 7, 2019 | Before the open | -1.00 | -0.96 | +4.0% |
| Feb 22, 2019 | Before the open | -1.05 | -1.19 | -13.3% |
| Oct 30, 2018 | Before the open | -1.06 | -1.14 | -7.5% |
| Aug 2, 2018 | Before the open | -1.06 | -1.00 | +5.7% |
| May 2, 2018 | Before the open | -0.96 | -0.87 | +9.4% |
| Feb 23, 2018 | Before the open | -0.64 | -0.85 | -32.8% |